(MENAFN- Newsfile Corp) New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-month price target of $4.00, representing over 80% upside from the Company's recent closing price of $2.20.

The initiation report highlights Immuron's proprietary polyclonal antibody platform, strong revenue growth from its over-the-counter product Travelan®, and an expanding clinical pipeline addressing major global infectious diseases. Near-term clinical milestones and U.S. regulatory developments add momentum to Immuron's investment outlook.

Key Highlights from the Initiation Report:

• Innovative Technology Platform: Immuron's orally delivered polyclonal antibodies, derived from hyperimmune bovine colostrum, offer a novel, non-antibiotic approach to treating and preventing gastrointestinal infections. The technology platform has broad applicability across multiple pathogens.

• Commercial Traction: The Company's flagship product, Travelan®, continues to post strong growth, with FY2025 revenue up 49% year-over-year to A$7.29 million. Travelan® is sold in Australia, the U.S., and Canada, and a third digestive health product, ProIBS®, is scheduled for Australian market launch in Q4 2025.

• Clinical Pipeline: Immuron's lead drug candidates, IMM-124E (Travelan®) and IMM-529, target traveler's diarrhea and Clostridioides difficile (C. difficile) infections, respectively. Both have shown promising Phase 2 data and are advancing toward pivotal trials in 2026.

• Strategic Partnerships: The Company collaborates with the U.S. Department of Defense, Walter Reed Army Institute of Research, and Monash University on multiple programs evaluating Immuron's antibodies for military and civilian applications.

• Strong Balance Sheet & Global Market Potential: Immuron remains debt-free, with product revenues helping offset R&D costs. The Company addresses multi-billion-dollar global markets in antimicrobial resistance and gastrointestinal therapeutics.

According to Emerging Growth Research's analysis, while Immuron faces typical biotechnology development and funding risks, its dual-revenue model, government partnerships, and late-stage clinical catalysts position the Company for significant long-term value creation.

For a copy of the full initiation report, please visit:

or
(on the right side of the page as you scroll down)

About Immuron Limited

Founded in 1994 and headquartered in Melbourne, Australia, Immuron Limited (Nasdaq: IMRN) is a commercial and clinical-stage biopharmaceutical company developing oral polyclonal antibodies for infectious diseases of the gastrointestinal tract. Its marketed products include Travelan® and Protectyn®, and its pipeline targets C. difficile, ETEC, and VRE infections.

MENAFN17102025004218003983ID1110212385